muscarinic antagonist

(redirected from Muscarinic antagonists)

mus·ca·rin·ic an·tag·o·nist

drugs that bind with muscarinic cholinergic receptors but do not activate them, thus preventing access to acetylcholine; examples include atropine, scopolamine, propantheline, and pirenzepine.
Mentioned in ?
References in periodicals archive ?
Despite recently approved dual combinations of Long Acting Muscarinic Antagonists (LAMA) and Long Acting Beta2 Agonists (LABA) bringing little novelty to the therapeutic party, companies remained focused on combination approaches.
The guideline addresses the use of numerous medications, alone or in combination, including short- and long-acting beta-2 agonists, short- and long-acting muscarinic antagonists, inhaled corticosteroids, inhaled long-acting anticholinergics, long-term macrolides, oral and IV systemic corticosteroids, roflumilast (when chronic bronchitis is present), oral slow-release theophylline, oral N-acetylcysteine, oral carbocysteine, and statins.
MCP(TM) based formulations created by Prosonix include optimally engineered dual and triple combinations of known drug products, including inhaled corticosteroids (ICS), long-acting beta-agonists (LABAs) and long-acting muscarinic antagonists (LAMAs).
interaction with muscarinic antagonists in isolated human bronchi
Since atropine is a non-selective muscarinic antagonists, the application of atropine blocks completely the effect produced by acetylcholine (Perry, 1971).
Our study also discusses these agents and technologies, among others: - Monoclonal antibodies - Muscarinic antagonists and beta-agonists (MABAs) - Once-daily combination products - Triple combination therapies - Generic combination drugs - Other novel small molecules including CRTH2 inhibitors.
The scientific rationale for combining long-acting [sz]2-agonists and muscarinic antagonists in COPD.
Individual alkaloids, ajmalicine, catharantine, and serpentine, were tested for effects as muscarinic antagonists.
The respiratory pipeline now comprises several classes of novel bronchodilating agents (Long acting muscarinic antagonists, bifunctional muscarinic antagonists-?
Relevant multi-drug combinations covered in the intellectual property include, but are not limited to, one or more of the following classes of inhaled therapeutics: long-acting muscarinic antagonists (LAMAs), long-acting beta-2 agonists (LABAs), short acting beta agonists (SABAs), inhaled corticosteroids (ICS) and antibiotics.
All current therapeutic approaches covered Long-acting muscarinic antagonists (LAMAs) Long-acting beta2 agonists (LABAs) Phosphodiesterase-IV (PDE-IV) inhibitors Coverage of both their use as monotherapies or in combination Expert Opinion for Real World Insights The data and analysis in the report is enriched through the specific insights and opinions of leading clinicians working in COPD in the US and Europe.